2052-1707

Pharmacology Research & Perspectives

Wiley (John Wiley & Sons)

View prefix report (10.1002)

Health Score

0 Excellent

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 444 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact444 DOIs
2

Add abstracts to 238 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact238 DOIs
3

Deposit reference lists for 143 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact143 DOIs

DOIs for this ISSN

Showing the top 5 of 1523 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Uricosuric targets of tranilast (10.1002/prp2.291)
Abstract ORCID
92.87 71
2 Effects of resveratrol on drug- and carcinogen-metabolizing… (10.1002/prp2.294)
Abstract ORCID
92.87 71
3 Analysis of drug combinations: current methodological landsc… (10.1002/prp2.149)
ORCID
74.78 979
4 Preclinical findings predicting efficacy and side‐effect pro… (10.1002/prp2.275)
Abstract ORCID
73.12 28
5 Chronic diazepam administration increases the expression of… (10.1002/prp2.283)
Abstract ORCID
72.36 27
6 A selective GPR40 (FFAR1) agonist LY2881835 provides immedia… (10.1002/prp2.278)
Abstract ORCID
66.11 20
7 In vitro analysis of factors influencing<i>CYP1A2</i>express… (10.1002/prp2.299)
Abstract ORCID
66.11 20
8 Targeting endosomal acidification by chloroquine analogs as… (10.1002/prp2.293)
Abstract
62.07 303
9 A phase 1 study comparing the proposed biosimilar BS-503a wi… (10.1002/prp2.286)
Abstract ORCID
61.52 16
10 Contribution of Sigma‐1 receptor to cytoprotective effect of… (10.1002/prp2.273)
Abstract ORCID
60.21 15
11 Mechanisms of the gabapentinoids and <i>α</i><sub>2</sub><i>… (10.1002/prp2.205)
ORCID
60.12 253
12 Structure-specific effects of lipidated oxytocin analogs on… (10.1002/prp2.290)
Abstract ORCID
58.80 14
13 Role of endoplasmic reticulum stress in drug‐induced toxicit… (10.1002/prp2.211)
ORCID
58.56 219
14 Application of a systems pharmacology model for translationa… (10.1002/prp2.270)
Abstract ORCID
57.31 13
15 GABA<sub>B</sub>receptor allosteric modulators exhibit pathw… (10.1002/prp2.288)
Abstract ORCID
57.31 13
16 Incorporation of concentration data below the limit of quant… (10.1002/prp2.131)
ORCID
57.08 191
17 Absorption, distribution, metabolism, and excretion of [<sup… (10.1002/prp2.281)
Abstract ORCID
55.70 12
18 The nocebo effect of drugs (10.1002/prp2.208)
ORCID
54.62 152
19 Rifampicin decreases exposure to sublingual buprenorphine in… (10.1002/prp2.271)
Abstract ORCID
53.96 11
20 Influence of age on intestinal bile acid transport in C57BL/… (10.1002/prp2.287)
Abstract ORCID
53.96 11
21 A pharmacokinetic evaluation and metabolite identification o… (10.1002/prp2.265)
Abstract ORCID
52.07 10
22 Mitochondrial fission – a drug target for cytoprotection or… (10.1002/prp2.235)
ORCID
51.70 116
23 Preclinical animal anxiety research – flaws and prejudices (10.1002/prp2.223)
ORCID
50.84 107
24 Anti‐inflammatory, antiapoptotic, and antioxidant activity o… (10.1002/prp2.231)
ORCID
50.22 101
25 Botulinum Neurotoxins Serotypes A and B induce paralysis of… (10.1002/prp2.289)
Abstract ORCID
50.00 9
26 Effect of <scp>CYP</scp>3A perpetrators on ibrutinib exposur… (10.1002/prp2.156)
ORCID
48.61 87
27 In vitro pharmacological profiling of R406 identifies molecu… (10.1002/prp2.175)
ORCID
48.61 87
28 <i>p</i>‐Cresyl sulfate, a uremic toxin, causes vascular end… (10.1002/prp2.92)
ORCID
48.24 84
29 Saroglitazar, a novel PPAR<i>α</i>/<i>γ</i> agonist with pre… (10.1002/prp2.136)
ORCID
47.71 80
30 The cardioprotective efficacy of <scp>TVP</scp>… (10.1002/prp2.272)
Abstract ORCID
47.71 8
31 Safety assessment in rats and dogs of Acoustic Cluster Thera… (10.1002/prp2.274)
Abstract ORCID
47.71 8
32 Pharmacology and physiology of gastrointestinal enteroendocr… (10.1002/prp2.155)
ORCID
47.30 77
33 Inhibition of SGLT2 alleviates diabetic nephropathy by suppr… (10.1002/prp2.239)
ORCID
47.30 77
34 Eslicarbazepine acetate for the treatment of focal epilepsy:… (10.1002/prp2.124)
ORCID
46.58 72
35 Dexmedetomidine preconditioning ameliorates kidney ischemia‐… (10.1002/prp2.45)
ORCID
46.28 70
36 Evaluation of biomarkers for in vitro prediction of drug‐ind… (10.1002/prp2.148)
ORCID
45.65 66
37 Acute cocaine exposure elicits rises in calcium in arousal-r… (10.1002/prp2.282)
Abstract ORCID
45.15 7
38 Population pharmacokinetic and exposure‐response analysis of… (10.1002/prp2.567)
ORCID
45.15 63
39 Pharmacological characterization of cebranopadol a novel ana… (10.1002/prp2.247)
ORCID
44.98 62
40 Perivascular adipose tissue contains functional catecholamin… (10.1002/prp2.41)
ORCID
44.98 62
41 Revisiting the putative role of heme as a trigger of inflamm… (10.1002/prp2.392)
ORCID
43.90 56
42 Effect of perampanel, a novel AMPA antagonist, on benzodiaze… (10.1002/prp2.63)
ORCID
43.70 55
43 An inhaled dose of budesonide induces genes involved in tran… (10.1002/prp2.243)
ORCID
43.31 53
44 Inhibition of adenosine deaminase (ADA)‐mediated metabolism… (10.1002/prp2.121)
ORCID
43.11 52
45 Azithromycin inhibits nuclear factor‐<i>κ</i>B activation du… (10.1002/prp2.58)
ORCID
43.11 52
46 Inhibition of Let‐7 micro<scp>RNA</scp> attenuates myocardia… (10.1002/prp2.56)
ORCID
42.90 51
47 Principles for inclusive implementation of the undergraduate… (10.1002/prp2.1023)
Abstract References
42.25 6
48 Antidepressant activity of fingolimod in mice (10.1002/prp2.135)
ORCID
42.25 48
49 Database search of spontaneous reports and pharmacological i… (10.1002/prp2.28)
ORCID
42.25 48
50 Metformin protects primary rat hepatocytes against oxidative… (10.1002/prp2.125)
ORCID
41.57 45